Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Asthma Therapeutics Market

Asthma Therapeutics Market Size

  • Report ID: GMI8394
  • Published Date: Mar 2024
  • Report Format: PDF

Asthma Therapeutics Market Size

Asthma Therapeutics Market size was valued at around USD 25.7 billion in 2023 and is estimated to grow at a CAGR of 4.4% between 2024 and 2032. This robust market growth can be attributed to factors such as the growing prevalence of asthma, rising expenditure on the R&D of novel biologics, and an increase in awareness regarding asthma management.


The growing prevalence of asthma places an increased burden on healthcare systems globally. According to the World Health Organization, asthma affected an estimated 262 million people in 2019 and caused 455,000 deaths around the globe. As a chronic condition that often requires long-term management, asthma necessitates ongoing medical attention, regular monitoring, and access to a diverse range of therapeutic options. This burden on healthcare systems underscores the imperative for continuous advancements and investment in asthma therapeutics.

Moreover, a crucial aspect fueling the growth of asthma therapeutics is the heightened awareness about asthma and improved diagnostic capabilities. The emphasis on early detection and intervention has led to more accurate diagnoses, enabling timely initiation of treatment. This increased awareness among healthcare professionals and the general population is fostering a proactive approach to asthma management.

Asthma therapeutics refer to the diverse range of medical interventions and treatments designed to manage and alleviate the symptoms of asthma, a chronic respiratory condition characterized by inflammation and constriction of the airways. Asthma therapeutics aim to address the underlying inflammation, bronchoconstriction, and airway hyperresponsiveness associated with asthma, providing patients with tailored and comprehensive strategies for the management of their condition.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global asthma therapeutics industry size was USD 25.7 billion in 2023 and is estimated to reach USD 37.8 billion by 2032, attributed to the growing prevalence of asthma and rising expenditure on the R&D of novel biologics.

The long-term asthma control medications treatment type segment in the market reached over USD 14.8 billion in 2023 and is poised to grow rapidly by 2032, due to their role to provide management of symptoms for ensuring sustained relief for individuals with asthma.

North America asthma therapeutics industry accounted for USD 10.2 billion in revenue in 2023 and is predicted to witness substantial growth over 2024 to 2032, driven by a robust healthcare infrastructure and extensive R&D initiatives.

AstraZeneca, Boehringer Ingelheim, Cipla Ltd., Covis Pharma, GSK plc, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc., Sanofi, Teva Pharmaceutical Industries Ltd. are some of the major industry contenders.

Asthma Therapeutics Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 10
  • Tables & Figures: 363
  • Countries covered: 22
  • Pages: 200
 Download Free Sample